ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2020

4:00PM-4:50PM: Abstract Number: 2031

Which Disease Activity Outcome Measure Discriminates Best in Axial Spondyloarthritis? A Systematic Literature Review and Meta-analysis

Spondyloarthritis Including Psoriatic Arthritis – Treatment III: Axial Spondyloarthritis (2028–2032)

4:00PM-4:50PM: Abstract Number: 2007

Whole Blood Transcriptional Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Adults with Moderately-to-Severely Active Rheumatoid Arthritis with Prior Inadequate Response to Methotrexate

RA – Treatments III: Predictors of Treatment Response (2003–2007)

5:00PM-5:50PM: Abstract Number: 2012

A Phase IIb, Randomized, Double-blind Study in Patients with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Patients with an Inadequate Response to Methotrexate

RA – Treatments IV: New Therapies & Strategies (2008–2012)

5:00PM-5:50PM: Abstract Number: 2018

Development and Validation of an Artificial Intelligence Approach for the Detection of Radiographic Sacroiliitis

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes III: Imaging in SpA (2018–2022)

5:00PM-5:50PM: Abstract Number: 2022

Effects of Anti-TNF-therapy on Osteoblastic Activity in Ankylosing Spondylitis – Results from a Prospective Study Using PET-MRI of SIJ and Spine

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes III: Imaging in SpA (2018–2022)

5:00PM-5:50PM: Abstract Number: 2011

Olokizumab Improves Patient Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate: Results from the Double-Blind, Randomized Controlled Phase III Study

RA – Treatments IV: New Therapies & Strategies (2008–2012)

5:00PM-5:50PM: Abstract Number: 2019

Preliminary Definition of a Positive MRI for Active Lesions in the Sacroiliac Joints Typical of Axial Spondyloarthritis

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes III: Imaging in SpA (2018–2022)

5:00PM-5:50PM: Abstract Number: 2020

Preliminary Definition of a Positive MRI for Structural Lesions in the Sacroiliac Joints in Axial Spondyloarthritis

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes III: Imaging in SpA (2018–2022)

5:00PM-5:50PM: Abstract Number: 2008

Should We Use Glucocorticoid in Early Rheumatoid Arthritis? : Results at 5 Years from the ERA Louvain Brussels Cohort

RA – Treatments IV: New Therapies & Strategies (2008–2012)

5:00PM-5:50PM: Abstract Number: 2010

Stable versus Tapered and Withdrawn Treatment with Tumor Necrosis Factor Inhibitor in Rheumatoid Arthritis Remission: A Randomized, Open-Label, Phase 4, Non-Inferiority Trial

RA – Treatments IV: New Therapies & Strategies (2008–2012)

5:00PM-5:50PM: Abstract Number: 2021

The Reliability of Scoring Sonographic Entheseal Abnormalities – the Diagnostic Ultrasound Enthesitis Tool (DUET) Study

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes III: Imaging in SpA (2018–2022)

5:00PM-5:50PM: Abstract Number: 2009

Treat-to Target for Early RA Patients in Usual Clinical Practice, a Randomized Study with a Favorable Effect of a Second Oral Pulse of Prednisolone. the Amsterdam COBRA Treat-to-target Study

RA – Treatments IV: New Therapies & Strategies (2008–2012)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].